A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
NCT00073476
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Males & females age 40-90 years
Enrolled in study within 6 hours of onset of stroke symptoms
Willing to sign informed consent form
No significant disabilities prior to stroke
Treatment with t-PA (tissue plasminogen activator)
Premorbid modified rankin scale score of 2 or more
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Halifax, Nova Scotia
- Hamilton, Ontario
- Hamilton, Ontario
- Hamilton, Ontario
- Ottawa, Ontario
- Montreal, Quebec
- Hyderabad, Nampally
- New Delhi,
- Birmingham, Alabama
- Mobile, Alabama
- Phoenix, Arizona
- Tucson, Arizona
- Little Rock, Arkansas
- Castro Valley, California
- La Jolla, California
- Long Beach, California
- Los Alamitos, California
- Los Angeles, California
- Los Angeles, California
- Orange, California
- Salinas, California
- San Diego, California
- San Francisco, California
- San Francisco, California
- Englewood, Colorado
- Grand Junction, Colorado
- Hartford, Connecticut
- New Haven, Connecticut
- Washington, District of Columbia
- Washington, District of Columbia
- Gainesville, Florida
- Jacksonville, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Sarasota, Florida
- Tampa, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Chicago, Illinois
- Chicago, Illinois
- Chicago, Illinois
- Chicago, Illinois
- Peoria, Illinois
- Springfield, Illinois
- Winfield, Illinois
- Iowa City, Iowa
- Kansas City, Kansas
- Lexington, Kentucky
- Louisville, Kentucky
- New Orleans, Louisiana
- Bangor, Maine
- Baltimore, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Worcester, Massachusetts
- Ann Arbor, Michigan
- Detroit, Michigan
- Detroit, Michigan
- Flint, Michigan
- Grand Rapids, Michigan
- Mount Clemens, Michigan
- Minneapolis, Minnesota
- Rochester, Minnesota
- Saint Paul, Minnesota
- Jackson, Mississippi
- Saint Louis, Missouri
- Springfield, Missouri
- Omaha, Nebraska
- Pennington, New Jersey
- Albuquerque, New Mexico
- Bronx, New York
- Brooklyn, New York
- Brooklyn, New York
- Brooklyn, New York
- Brooklyn, New York
- Brooklyn, New York
- Buffalo, New York
- Manhasset, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- Rochester, New York
- Greensboro, North Carolina
- Winston-Salem, North Carolina
- Cincinnati, Ohio
- Cleveland, Ohio
- Cleveland, Ohio
- Cleveland, Ohio
- Columbus, Ohio
- Dayton, Ohio
- Toledo, Ohio
- Oklahoma City, Oklahoma
- Portland, Oregon
- Allentown, Pennsylvania
- Philadelphia, Pennsylvania
- Pittsburgh, Pennsylvania
- Providence, Rhode Island
- Charleston, South Carolina
- Columbia, South Carolina
- Greenville, South Carolina
- Nashville, Tennessee
- Dallas, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- Charlottesville, Virginia
- Richmond, Virginia
- Seattle, Washington
- Seattle, Washington
- Morgantown, West Virginia
- Milwaukee, Wisconsin
- La Mesa, California
- Los Angeles, California
- Los Angeles, California
- Sacramento, California
- Stanford, California
- Honolulu, Hawaii
- Burlington, Massachusetts
- Saint Louis, Missouri
- Asheville, North Carolina
- Akron, Ohio
- Memphis, Tennessee
- Edinburg, Texas
- Harlingen, Texas
- La Mesa, California
- Atlanta, Georgia
- Fort Wayne, Indiana
- Fort Wayne, Indiana
- Louisville,, Kentucky
- Louisville, Kentucky
- Salisbury, North Carolina
- Dayton, Ohio
- Dayton, Ohio
- Dayton, Ohio
- Dayton, Ohio
- Allentown, Pennsylvania
- Philadelphia, Pennsylvania
- Tartu,
- Bad Neustadt,
- Freiburg,
- Leipzig,
- Luebeck,
- Budapest,
- Gyor,
- Pavia,
- Perugia,
- Coimbra,
- Lisboa,
- Singapore,
- Singapore,
- Santiago de Compostela, Galicia
- Madrid,
- Madrid,
- Zaragoza,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke | |||
Official Title ICMJE | A Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a 72-Hour Infusion of CP-101,606 in Subjects With Acute Ischemic Stroke. | |||
Brief Summary | The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment | |||
Condition ICMJE | Stroke | |||
Intervention ICMJE | Drug: traxiprodil (CP-101,606) | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Enrollment ICMJE | 300 | |||
Original Enrollment ICMJE | Not Provided | |||
Study Completion Date ICMJE | February 2005 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria: Males & females age 40-90 years Enrolled in study within 6 hours of onset of stroke symptoms Willing to sign informed consent form No significant disabilities prior to stroke Exclusion Criteria: Treatment with t-PA (tissue plasminogen activator) Premorbid modified rankin scale score of 2 or more | |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 40 Years to 90 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Estonia, Germany, Hungary, Italy, Portugal, Singapore, Spain, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00073476 | |||
Other Study ID Numbers ICMJE | A1611005 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | June 2006 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |